Role of brain 2-[18F]fluoro-2-deoxy-D-glucose-positron-emission tomography as survival predictor in amyotrophic lateral sclerosis.

Purpose: The identification of prognostic tools in amyotrophic lateral sclerosis (ALS) would improve the design of clinical trials, the management of patients, and life planning. We aimed to evaluate the accuracy of brain 2-[18F]fluoro-2-deoxy-D-glucose-positron-emission tomography (2-[18F]FDG-PET)...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Nuclear Medicine & Molecular Imaging Vol. 50; no. 3; pp. 784 - 792
Autores principales: Canosa, Antonio, Martino, Alessio, Manera, Umberto, Vasta, Rosario, Grassano, Maurizio, Palumbo, Francesca, Cabras, Sara, Di Pede, Francesca, Arena, Vincenzo, Moglia, Cristina, Giuliani, Alessandro, Calvo, Andrea, Chiò, Adriano, Pagani, Marco
Formato: Journal Article
Publicado: Springer Nature Feb2023
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=161397712&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 161397712
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        16197070
        NPC
      jtl: European Journal of Nuclear Medicine & Molecular Imaging
      issn: 16197070
      maglogo: N
    pubinfo:
      dt: Feb2023
      vid: 50
      iid: 3
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        161397712
        159894397
        10.1007/s00259-022-05987-3
        161397712
      ppf: 784
      ppct: 8
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Role of brain 2-[18F]fluoro-2-deoxy-D-glucose-positron-emission tomography as survival predictor in amyotrophic lateral sclerosis.
      aug:
        au:
          Canosa, Antonio
          Martino, Alessio
          Manera, Umberto
          Vasta, Rosario
          Grassano, Maurizio
          Palumbo, Francesca
          Cabras, Sara
          Di Pede, Francesca
          Arena, Vincenzo
          Moglia, Cristina
          Giuliani, Alessandro
          Calvo, Andrea
          Chiò, Adriano
          Pagani, Marco
        affil: ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy
      sug:
      ab: Purpose: The identification of prognostic tools in amyotrophic lateral sclerosis (ALS) would improve the design of clinical trials, the management of patients, and life planning. We aimed to evaluate the accuracy of brain 2-[18F]fluoro-2-deoxy-D-glucose-positron-emission tomography (2-[18F]FDG-PET) as an independent predictor of survival in ALS. Methods: A prospective cohort study enrolled 418 ALS patients, who underwent brain 2-[18F]FDG-PET at diagnosis and whose survival time was available. We discretized the survival time in a finite number of classes in a data-driven fashion by employing a k-means-like strategy. We identified "hot brain regions" with maximal power in discriminating survival classes, by evaluating the Laplacian scores in a class-aware fashion. We retained the top-m features for each class to train the classification systems (i.e., a support vector machine, SVM), using 10% of the ALS cohort as test set. Results: Data were discretized in three survival profiles: 0–2 years, 2–5 years, and > 5 years. SVM resulted in an error rate < 20% for two out of three classes separately. As for class one, the discriminant clusters included left caudate body and anterior cingulate cortex. The most discriminant regions were bilateral cerebellar pyramid in class two, and right cerebellar dentate nucleus, and left cerebellar nodule in class three. Conclusion: Brain 2-[18F]FDG-PET along with artificial intelligence was able to predict with high accuracy the survival time range in our ALS cohort. Healthcare professionals can benefit from this prognostic tool for planning patients' management and follow-up. 2-[18F]FDG-PET represents a promising biomarker for individual patients' stratification in clinical trials. The lack of a multicentre external validation of the model warrants further studies to evaluate its generalization capability.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N